Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (305)	9/3/2002 11:32:21 PM
From: Biomaven	Respond to of 508

Trial design is always easy in retrospect. Kind of like investing. :) That said, I absolutely agree with phudoc's bottom line - that there is a very good chance of the trial continuation providing some more statistical goodies for ITMN and the indication ultimately being approved. I keep coming back to one central point - it would be unethical to repeat this trial, because to do so would, with high degree of likelihood, involve killing some of the placebo patients. Given that, how can the FDA ultimately not approve this indication based on these results? Peter